BMS scales back at former Novartis plant, shifting cell therapy vector production to MA
Bristol Myers Squibb will cease production of viral vectors from its plant in Libertyville, Illinois, the company has told Fierce Pharma. The facility, which was previously used by Novartis to manufacture the gene therapy Zolgensma, was picked up by BMS in early 2023 to bolster viral vector capacity for its commercial cell therapy portfolio.
Bristol Myers Squibb will cease production of viral vectors from its plant in Libertyville, Illinois, the company has told Fierce Pharma. The facility, which was previously used by Novartis to manufacture the gene therapy Zolgensma, was picked up by BMS in early 2023 to bolster viral vector capacity for its commercial cell therapy portfolio.
